Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
|Headquarters||249 E. Grand Avenue|
SOUTH SAN FRANCISCO, CA, United States 94080
|Chairman of the Board, President, Chief Executive Officer||N. Anthony Coles|
|Chief Financial Officer, Executive Vice President||Matthew Fust|
|Executive Vice President, General Counsel, Corporate Secretary||Suzanne Shema|
|Executive Vice President - Global Research & Development and Technical Operations||Pablo Cagnoni|
|Executive Vice President - Corporate Development and Strategy||Juergen Lasowski|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||72.7M||Book Value||$12.15|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||15.8|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-57.14%|
*GAAP = prior to non-GAAP analyst adjusted earnings.